Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 1, 1998, Pages 39-45

  Aviram, Michael ^a   Hussein, Osamah ^a   Rosenblat, Mira ^a   Schlezinger, Sorina ^a   Hayek, Tony ^a   Keidar, Shlomo ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase inhibitors; Low density lipoprotein (LDL); Macrophages; Oxidized LDL; Platelets

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PROBUCOL;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ADULT; AGED; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD PLATELETS; CELL COMMUNICATION; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LIPID PEROXIDATION; LIPOPROTEINS; LIPOPROTEINS, LDL; LOVASTATIN; MACROPHAGES; MICE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 0031985499     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199801000-00006     Document Type: Article

References (44)

1. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993;98:1-9.
2. Aviram M. Beyond cholesterol: modification of lipoproteins and increased atherogenicity. In: Neri Serneri GG, Gensini GF, Abbate R, Prisco D, eds. Atherosclerosis, inflammation and thrombosis. Florence, Italy: Scientific Press, 1993:15-36.
3. Ross R. Platelet derived growth factor. Annu Rev Med 1987; 38:71-9.
4. Aviram M. Macrophage-mediated oxidation of LDL and atherosclerosis. In: Bellomo G, Rice-Evans C, eds. Free radicals, lipoprotein oxidation and atherosclerosis: biological and clinical aspects. London: Richelieu Press, 1995:101-37.
5. Aviram M. Effect of lipoproteins and platelets on macrophage cholesterol metabolism. In: Harris JR, ed. Blood cell biochemistry. New York: Plenum Press, 1992:179-208.
6. Sevitt S. Platelets and foam cells in the evolution of atherosclerosis: histological and immunological studies of human lesions. Atherosclerosis 1986;61:107-10.
7. Aviram M. LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Thromb Haemost 1995;74:560-4.
8. Aviram M. Platelets and arterial wall lesion. Curr Opin Lipidol 1992;3:344-8.
9. Aviram M, Brook JG. Platelet activation by plasma lipoproteins. Prog Cardiovasc Dis 1987;30;61-72.
10. Brook JG, Aviram M. Platelet-lipoprotein interaction. Semin Thromb Haemost 1988;14:258-65.
11. Aviram M. Platelet-modified low-density lipoprotein: studies in normals and in patients with homozygous familial hypercholesterolemia. Clin Biochem 1987;20:91-5.
12. Aviram M, Brook JG. Platelet enhancement of macrophage cholesterol accumulation: a novel mechanism for atherogenesis. In: Halpern MJ, ed. Molecular biology of atherosclerosis. Proceedings of the 57th European Atherosclerosis Society Meeting. London: J Libbey, 1992:67-71.
13. Aviram M, Fuhrman B, Brook JG. Platelet-mediated macrophage cholesterol accumulation. In: Stein O, Eisenberg S, Stein Y. eds. Atherosclerosis IX. Proceedings of the Ninth International Symposium on Atherosclerosis. Rosemont-Chicago, IL, USA; Tel-Aviv, Israel: R and L Creative Communications, 1992:523-6.
14. Aviram M. The effect of platelet on macrophage lipoprotein metabolism. Atherosclerosis 1988;73:269-71.
15. Aviram M, Fuhrman B, Keidar S, et al. Platelet-modified low density lipoprotein induces macrophage cholesterol accumulation and platelet activation. J Clin Chem Clin Biochem 1989;27:3-12.
16. Kruth HS. Platelet-mediated cholesterol accumulation in cultured aortic smooth muscle cells. Science 1985;227:1243-5.
17. Mendelsohn ME, Loscalzo J. Role of platelets in cholesteryl ester formation by U-937 cells. J Clin Invest 1988;81:62-8.
18. Curtiss LK, Black AA, Takagi Y, Plow EF. New mechanisms for foam cell generation in atherosclerotic lesions. J Clin Invest 1987;80:367-73.
19. Maor I, Brook JG, Aviram M. Platelet secreted lipoprotein-like particle is taken up by the macrophage scavenger receptor and enhances cellular cholesterol accumulation. Atherosclerosis 1991; 88:163-74.
20. Aviram M. Platelet secretory products enhance LDL receptor activity and inhibit scavenger receptor activity in human monocyte-derived macrophages. Metabolism 1989;38:425-30.
21. Fuhrman B, Brook JG, Aviram M. Lipid-protein particles secreted from activated platelets reduce macrophage uptake of low density lipoprotein. Atherosclerosis 1991;89:163-73.
22. Fuhrman B, Brook JG, Aviram M. Proteins derived from platelet alpha granules modulate the uptake of oxidized low density lipoprotein by macrophages. Biochim Biophys Acta 1992; 1127: 15-21.
23. Fuhrman B, Brook JG, Aviram M. Activated platelets secrete a protein-like factor that stimulates oxidized-LDL receptor activity in macrophages. J Lipid Res 1991;32:1113-23.
24. Hussein O, Brook JG, Aviram M. Intraperitoneal injection of platelet secretory products into mice increases macrophage uptake of oxidized low density lipoprotein. Isr J Med Sci 1993;29: 453-9.
25. Aviram M, Furman B, Maor I, Brook GJ. Serotonin increases macrophage uptake of oxidized low density lipoprotein. Eur J Clin Chem Clin Biochem 1992;30:55-61.
26. Aviram M, Dankner G, Brook JG. Platelet secretory products increase LDL oxidation, enhance its uptake by macrophages and reduce its fluidity. Arteriosclerosis 1990;10:559-63.
27. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 1987;76:504-7.
28. Lavy A, Brook JG, Dankner G, Ben Amotz A, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 1991;40:794-9.
29. Aviram M, Rosenblat M, Brook JG. Secretory products from human monocyte-derived macrophages enhance platelet aggregation. Metabolism 1991;40:270-4.
30. Chiamori N, Henry RJ. Study of the ferric chloride method for determination of total cholesterol and cholesteryl esters. Am J Clin Pathol 1959;31:305-9.
31. Rouser G, Fleischer S, Yamamoto A. Two dimensional thin layer chromatography of polar lipids and determination of phospholipids by phosphorous analysis of spots. Lipids 1970;5:494-6.
32. Frei B, Stoker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A 1988;85:9748-52.
33. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-10.
34. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 1983;30:111-8.
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RS. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193: 265-75.
36. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75.
37. Hochgraf E, Levy Y, Aviram M, Brook JG, Cogan U. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism 1994;43:11-7.
38. Hussein O, Rosenblat M, Schlesinger A, Keldar S, Aviram A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol (in press).
39. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992;41:229-35.
40. Hoffman R, Brook JG, Aviram M. Hypolipidemic therapy reduces lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992;93:105-13.
41. Aviram M, Keidar S, Brook JG. Dual effect of lovastatin and simvastatin on LDL-macrophage interaction. Eur J Clin Chem Clin Biochem 1991;29:657-64.
42. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low-density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997;128:11-8.
43. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 1994;201:1567-74.
44. Aviram M, Maor I, Keidar S, et al. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem Biophys Res Commun 1995;216:501-13.